source
- Lilly's Foundayo obesity pill posts $98 million Q2 sales, trails Novo's WegovyEli Lilly introduced its oral obesity treatment Foundayo after receiving FDA approval in April 2025. The drug entered the market in the second quarter of 2026, marking Lilly's first foray into an o…
- Gilead's HIV prevention shot Yeztugo posts $232 million Q2 sales, beating forecastsGilead reported that its biannual injectable for HIV pre‑exposure prophylaxis, Yeztugo, generated $232 million in revenue during the second quarter. This figure exceeds analysts' consensus estimat…